Dapagli ozin effects of biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF Trial. Circulation. 2019;140: 1463 76. 34. Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 in- hibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR- Reduced and DAPA-HF trials. Lancet. 2020;396:819 29. 35. Hickey A, Suna J, Marquart L, et al. Improving medication titration in heart failure by embedding a structured medication titration plan. Int J Cardiol. 2016;224:99 106. 36. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/ EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739 91. 37. Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for second- ary mitral regurgitation. N Engl J Med. 2018;379:2297 306. 38. Asch FM, Grayburn PA, Siegel RJ, et al. Echocar- diographic outcomes after transcatheter lea et approximation in patients with secondary mitral regurgitation: the COAPT trial. J Am Coll Cardiol. 2019; 74:2969 79. 39. Kang DH, Park SJ, Shin SH, et al. Angiotensin re- ceptor neprilysin inhibitor for functional mitral regur- gitation. Circulation. 2019;139:1354 65. 40. Merit-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in-congestive heart failure (MERIT- HF). Lancet. 1999;353:2001 7. 41. CIBIS-II Investigators Committee. The cardiac insuf ciency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9 13. J Maddox et al. 42. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349 55. 43. Bristow MR, Gilbert EM, Abraham WT, et al. Car- vedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circula- tion. 1996;94:2807 16. 44. 